As part of the BioInnovation Institute (BII)  latest Venture Lab program, Lausanne-based Beech Biotech has been awarded €500'000 to further develop a placenta-impermeable antibody to treat preeclampsia.

作为生物创新研究所（BII）最新的风险实验室计划的一部分，洛桑的Beech Biotech公司获得了50万欧元，用于进一步开发一种胎盘不可渗透的抗体以治疗子痫前期。

Preeclampsia represents a significant unmet medical need in women’s health, claiming the lives of approximately 70,000 women and 500,000 babies annually worldwide. The condition, characterized by high blood pressure and organ damage during pregnancy, currently lacks effective treatment options beyond the delivery of the baby, which can be dangerous when occurring prematurely..

子痫前期是女性健康领域中一个重要的未满足医疗需求，全球每年约有7万名妇女和50万名婴儿因此丧生。该病的特征是孕期出现高血压和器官损伤，目前除了分娩之外，尚无其他有效治疗手段，而早产可能带来危险。

Beech Biotech

山毛榉生物技术

is developing a novel placenta-impermeable antibody designed to address the root causes of preeclampsia while ensuring the treatment doesn’t cross the placental barrier—a critical safety feature for maternal medications. The company is collaborating with a network of expert industry consultants and contractors to advance the technology toward clinical applications..

正在开发一种新型的胎盘不可渗透抗体，旨在解决先兆子痫的根本原因，同时确保治疗不会跨越胎盘屏障——这是母体药物的一项关键安全特性。该公司正与一批专业的行业顾问和承包商合作，推动该技术向临床应用迈进。

Founded in 2022, the startup has been selected to participate in the

成立于 2022 年的这家初创公司已被选中参与

BioInnovation Institute

生物创新研究院

’s (BII) Venture Lab program to accelerate the development of its solution. It has received an investment of €500 as part of the program.

通过BII的Venture Lab项目来加速其解决方案的开发。作为该项目的一部分，它已获得500欧元的投资。

“BII’s investment in Beech Biotech is a great endorsement of our project to bring a new treatment for preeclampsia to women and their babies. The BII network also provides a perfect springboard for our Series A fundraising, planned later in the year,” said Ian Cottingham, CEO and Founder of Beech Biotech..

“BII对榉树生物技术公司的投资是对我们为女性及其婴儿带来先兆子痫新疗法项目的极大认可。BII网络还为我们计划在今年晚些时候进行的A轮融资提供了完美的跳板，”榉树生物技术公司首席执行官兼创始人伊恩·科廷厄姆表示。

The BioInnovation Institute, based in Copenhagen, Denmark, supports life science startups and projects through various programs designed to help early-stage companies bridge the gap between research and commercialization. The Venture Lab program specifically provides funding, business development support, and access to a network of investors and industry partners..

位于丹麦哥本哈根的生物创新研究所通过各种项目支持生命科学初创公司和项目，旨在帮助早期公司弥合研究与商业化之间的差距。其中，风险实验室项目专门提供资金、商业发展支持，并为投资者和行业合作伙伴网络提供对接机会。

(Press release/RAN)

（新闻稿/随机接入网络）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送